Medicare seeks comments for Alzheimer’s treatment national coverage policy
The Centers for Medicare & Medicaid Services is accepting comments through Aug. 11 on whether to establish a national Medicare coverage policy for monoclonal antibodies to treat Alzheimer’s disease.
The Food and Drug Administration recently approved the first such drug (aducanumab) through an accelerated pathway that requires the company to verify clinical benefit in a post-approval trial. Medicare administrative contractors are currently making coverage determinations for aducanumab at the local level.
Stakeholders may register for CMS webinars July 22 to learn more or comment. CMS plans to release a proposed decision within six months and a final decision within nine months.
Related News Articles
Headline
The AHA July 11 released its quarterly Health Care Plan Accountability Update, a roundup of news, letters, statements and other resources covering private…
Headline
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs. The AHA…
Headline
The Centers for Medicare & Medicaid Services July 10 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
The Healthcare Equality Network July 3 sent a letter to the Centers for Medicare & Medicaid Services, expressing concerns about claims denials by…
Headline
The Department of Health and Human Services’ Office of Inspector General last week announced its intent to investigate Medicare Advantage Organizations’ prior…
Headline
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…